Amgen, Selexis Expand Deal to Include Evaluation of Mammalian Cell Line | GenomeWeb

NEW YORK (GenomeWeb News) – Amgen expanded an R&D licensing agreement to include the evaluation of Selexis' Sure Cho-M Cell Line.

Under the terms of the deal announced today by Selexis, Amgen will assess the cell line in conjunction with the Selexis SUREtech Vectors for improved R&D. Sure Cho-M Cell Line is a mammalian cell line derived from CHO-K1 cells and is for producing therapeutic recombinant proteins and monoclonal antibodies.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.